February 7, 2023 03:57 PM ESTUpdated February 8, 09:12 AM
Pharma
Marketing

Re­searchers pan phar­ma DTC ad­ver­tis­ing for high spend­ing on low-val­ue drugs — JA­MA re­port

Beth Snyder Bulik

Senior Editor

New re­search is look­ing to con­nect the dots be­tween di­rect-to-con­sumer (DTC) ad­ver­tis­ing and low­er clin­i­cal ben­e­fits or ther­a­peu­tic val­ue. A

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times